Latest Pharma Insights
ASH: Ryvu Makes The Case For Romaciclib In AML
The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.
Scrip - December 8, 2025
The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.
Scrip - December 8, 2025
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow
The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.
Scrip - December 8, 2025
The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.
Scrip - December 8, 2025
OTC Firms Must Strike Delicate Balance Between Trust And Personalization
“In the coming years, growth will depend on whether brands can combine trust, personalization, and proof of evidence into one coherent prevention experience,” argue Simon Kucher's Clemens Oberhammer and Christian Rebholz in this exclusive interview.
HBW Insight - December 8, 2025
“In the coming years, growth will depend on whether brands can combine trust, personalization, and proof of evidence into one coherent prevention experience,” argue Simon Kucher's Clemens Oberhammer and Christian Rebholz in this exclusive interview.
HBW Insight - December 8, 2025
GDUFA Costs ‘Destroy Economics’ Of Onshoring Generics, Cuban Warns
Cuban argues that user fees under the GDUFA program are deterring domestic production of generics, according to reports.
Generics Bulletin - December 8, 2025
Cuban argues that user fees under the GDUFA program are deterring domestic production of generics, according to reports.
Generics Bulletin - December 8, 2025
Wherever Medtech Goes, AI Will Have One Hand On The Steering Wheel
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
Biopharma In 2026: From Darwinian Reset To Disciplined Growth
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next?
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025
ASH: Disc Set for Busy 2026 After Promising Interim Anemia Drug Data
The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.
Scrip - December 8, 2025
The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.
Scrip - December 8, 2025
Saya-Enze Partnership Signals Growing Momentum For Biosimilars In Mexico
Collaboration aims to bring two biosimilars for osteoporosis and osteoarthritis to Mexico, with Saya leading commercialization and Enzene overseeing development and manufacturing.
Generics Bulletin - December 8, 2025
Collaboration aims to bring two biosimilars for osteoporosis and osteoarthritis to Mexico, with Saya leading commercialization and Enzene overseeing development and manufacturing.
Generics Bulletin - December 8, 2025
Pipeline Watch: One Approval And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 8, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 8, 2025
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex
After years of fighting and securing treatment for her daughter, cystic fibrosis campaigner Gayle Pledger could not leave other patients behind. This is a story of families coming together and finding a generic drug manufacturer in order to save their children.
Generics Bulletin - December 8, 2025
After years of fighting and securing treatment for her daughter, cystic fibrosis campaigner Gayle Pledger could not leave other patients behind. This is a story of families coming together and finding a generic drug manufacturer in order to save their children.
Generics Bulletin - December 8, 2025
Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Scrip - December 8, 2025
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Scrip - December 8, 2025
Hanmi Expands Obesity Interests To Aging Under New Five-Year Roadmap
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
Scrip - December 8, 2025
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
Scrip - December 8, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Scrip - December 8, 2025
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Scrip - December 8, 2025
US FDA Advisory Committees: Analysis Finds Most Public Hearing Speakers Favor Approval
The tilt toward approval extended beyond patients and advocates to clinicians, professional societies and industry.
HBW Insight - December 8, 2025
The tilt toward approval extended beyond patients and advocates to clinicians, professional societies and industry.
HBW Insight - December 8, 2025
Two Strikes And Firms Selling 7-OH Supplements Will Be Out Of Options To Avoid US Enforcement
Enforcements at facilities in Missouri operated by Shaman Botanicals and Relax Relief Rejuvenate Trading were preceded by administrative detention orders, FDA’s first use of the authority since its reorganization in October 2024.
HBW Insight - December 8, 2025
Enforcements at facilities in Missouri operated by Shaman Botanicals and Relax Relief Rejuvenate Trading were preceded by administrative detention orders, FDA’s first use of the authority since its reorganization in October 2024.
HBW Insight - December 8, 2025
ASH: Ryvu Makes The Case For Romaciclib In AML
The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.
Scrip - December 8, 2025
The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.
Scrip - December 8, 2025
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow
The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.
Scrip - December 8, 2025
The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.
Scrip - December 8, 2025
ASH: Disc Set for Busy 2026 After Promising Interim Anemia Drug Data
The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.
Scrip - December 8, 2025
The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.
Scrip - December 8, 2025
Pipeline Watch: One Approval And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 8, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 8, 2025
Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Scrip - December 8, 2025
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Scrip - December 8, 2025
Hanmi Expands Obesity Interests To Aging Under New Five-Year Roadmap
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
Scrip - December 8, 2025
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
Scrip - December 8, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Scrip - December 8, 2025
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Scrip - December 8, 2025
CorWave Ready To Dive Into LVAD Market Following First-In-Human Study
The French start-up has successfully implanted its ‘fishtail’ LVAD in a patient for 84 days, where it served as an effective bridge to transplant. Medtech Insight spoke to the company’s CEO, Louis de Lillers, to hear more about the company’s progress and his take on the evolving LVAD market.
Medtech Insight - December 5, 2025
The French start-up has successfully implanted its ‘fishtail’ LVAD in a patient for 84 days, where it served as an effective bridge to transplant. Medtech Insight spoke to the company’s CEO, Louis de Lillers, to hear more about the company’s progress and his take on the evolving LVAD market.
Medtech Insight - December 5, 2025
Olympus Hits Another Endoscope Snag, Updates Instructions For PolyLoop After 113 Serious Injuries
The US FDA says Olympus has updated its instructions for a device used in many endoscopic procedures after reports of serious injuries. The class I recall follows the FDA blocking imports of other scoping devices from the Japanese firm earlier this year.
Medtech Insight - December 5, 2025
The US FDA says Olympus has updated its instructions for a device used in many endoscopic procedures after reports of serious injuries. The class I recall follows the FDA blocking imports of other scoping devices from the Japanese firm earlier this year.
Medtech Insight - December 5, 2025
Medtronic’s Hugo RAS Gets FDA Nod For Urologic Procedures, But Intuitive Still Leads, Analyst Says
Medtronic won FDA clearance for its Hugo surgical robot for urologic procedures, which Wiliam Blair analyst expects will draw interest from physicians. But he also says that Intuitive Surgical will remain the clear dominant player.
Medtech Insight - December 5, 2025
Medtronic won FDA clearance for its Hugo surgical robot for urologic procedures, which Wiliam Blair analyst expects will draw interest from physicians. But he also says that Intuitive Surgical will remain the clear dominant player.
Medtech Insight - December 5, 2025
NICE Rules-Based Pathway Tops Conference Talking Points For UK Healthtechs
Digital technology and AI have pushed healthcare delivery to a transformational turning point, but market access, budget constraints and scaling adoption of innovation remain the eternal challenges for healthtech manufacturers.
Medtech Insight - December 5, 2025
Digital technology and AI have pushed healthcare delivery to a transformational turning point, but market access, budget constraints and scaling adoption of innovation remain the eternal challenges for healthtech manufacturers.
Medtech Insight - December 5, 2025
OTC Firms Must Strike Delicate Balance Between Trust And Personalization
“In the coming years, growth will depend on whether brands can combine trust, personalization, and proof of evidence into one coherent prevention experience,” argue Simon Kucher's Clemens Oberhammer and Christian Rebholz in this exclusive interview.
HBW Insight - December 8, 2025
“In the coming years, growth will depend on whether brands can combine trust, personalization, and proof of evidence into one coherent prevention experience,” argue Simon Kucher's Clemens Oberhammer and Christian Rebholz in this exclusive interview.
HBW Insight - December 8, 2025
US FDA Advisory Committees: Analysis Finds Most Public Hearing Speakers Favor Approval
The tilt toward approval extended beyond patients and advocates to clinicians, professional societies and industry.
HBW Insight - December 8, 2025
The tilt toward approval extended beyond patients and advocates to clinicians, professional societies and industry.
HBW Insight - December 8, 2025
Two Strikes And Firms Selling 7-OH Supplements Will Be Out Of Options To Avoid US Enforcement
Enforcements at facilities in Missouri operated by Shaman Botanicals and Relax Relief Rejuvenate Trading were preceded by administrative detention orders, FDA’s first use of the authority since its reorganization in October 2024.
HBW Insight - December 8, 2025
Enforcements at facilities in Missouri operated by Shaman Botanicals and Relax Relief Rejuvenate Trading were preceded by administrative detention orders, FDA’s first use of the authority since its reorganization in October 2024.
HBW Insight - December 8, 2025
GDUFA Costs ‘Destroy Economics’ Of Onshoring Generics, Cuban Warns
Cuban argues that user fees under the GDUFA program are deterring domestic production of generics, according to reports.
Generics Bulletin - December 8, 2025
Cuban argues that user fees under the GDUFA program are deterring domestic production of generics, according to reports.
Generics Bulletin - December 8, 2025
Saya-Enze Partnership Signals Growing Momentum For Biosimilars In Mexico
Collaboration aims to bring two biosimilars for osteoporosis and osteoarthritis to Mexico, with Saya leading commercialization and Enzene overseeing development and manufacturing.
Generics Bulletin - December 8, 2025
Collaboration aims to bring two biosimilars for osteoporosis and osteoarthritis to Mexico, with Saya leading commercialization and Enzene overseeing development and manufacturing.
Generics Bulletin - December 8, 2025
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex
After years of fighting and securing treatment for her daughter, cystic fibrosis campaigner Gayle Pledger could not leave other patients behind. This is a story of families coming together and finding a generic drug manufacturer in order to save their children.
Generics Bulletin - December 8, 2025
After years of fighting and securing treatment for her daughter, cystic fibrosis campaigner Gayle Pledger could not leave other patients behind. This is a story of families coming together and finding a generic drug manufacturer in order to save their children.
Generics Bulletin - December 8, 2025
Wherever Medtech Goes, AI Will Have One Hand On The Steering Wheel
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025
Biopharma In 2026: From Darwinian Reset To Disciplined Growth
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next?
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025